.png)
HIV Revolution on EFDA
HIV REVOLUTION
Hiv-Aids research using innovative technology we Scientific Federation proudly organizing 2nd International Conference & Expo on HIV&AIDS which will be held on September 17-18, 2018 at Toronto, Canada.
In the recent study, an injectable antiretroviral therapy (ART) contains 2 drugs Rilpivirine and Cabotegravir it has to administrate for every 4 or 8 weeks may be as effective as a daily oral dose of the drug in maintaining viral suppression in patients with HIV.
The Introduction of a single tablet in ART dosing it’s represented a leap forward and it can be long-acting it may represent the next revolution in HIV therapy.
DR. Hiroshi Ohrui the Professor of the Yokohama University of Pharmacy. He explained about An Extremely Excellent Anti-HIV Nucleosides, 4-C-Ethynyl-2-fluoro-2-deoxyadenosine (EFDA) has attached much attention due to its extremely excellent anti-HIV activity, for example EFDA prevents the emergence of resistant HIV mutants and is over 400 times more active than AZT and several orders of magnitude more active than the other clinical reverse-transcriptase inhibitory 2’,3’-dideoxy-nucleosides drug, very low toxic, very long-acting, very useful for the prevention of HIV-Infection.
For the design of the modified nucleoside which could solve the problems that the clinical drugs have (1. emergence of drug-resistant HIV mutants, 2. The adverse effect of drugs, 3. The necessity to take quite a few amounts of drugs), the following working hypotheses were proposed. They are (1) the way to prevent the emergence of drug-resistant HIV mutants, (2) the way to decrease the toxicity of modified nucleosides, (3) the way to provide the modified nucleoside with stability to both enzymatic and acidic glycolysis for long-acting.
HIV-AIDS-2018 cordially invites researchers, scientists, professors, delegates and students from all over the world exchange information on HIV-AIDS which contains plenary sessions, keynote speeches, poster, and oral presentations on HIV-AIDS On Emerging area on Immunology, Microbiology, Infection&Imunnity, Public Health, Infectious Diseases, Virology, Pathology, Psychology, Biochemistry, Epidemiology, Gynecology, Global Health, and Population Health.
0 comments: